PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs AZNCF |
|---|---|---|---|---|---|
| ALPMF | Astellas Pharma Inc. | 0.00 | 0.1 | 20.4% | -100% |
| NONOF | Novo Nordisk A/S | 0.06 | 1.3 | 20.6% | -96% |
| NVSEF | Novartis AG | 1.61 | 24.2 | 15.0% | +7% |
| ASMLF | ASML Holding N.V. | 2.70 | 64.3 | 23.8% | +79% |